Earnings Summary on United Therapeutics

United Therapeutics (UTHR) reported Q2 2025 GAAP revenue of $798.6 million and EPS of $6.41, both up year-over-year but falling short of consensus estimates by $3.27 million and $0.88 respectively. Despite record top-line performance driven by robust growth in the Tyvaso franchise, which now comprises 58.8% of total revenue, profitability was impacted by a 20% surge in SG&A expenses. The company projects continued double-digit revenue growth, supported by pipeline advancements and a strong balance sheet, though investors should monitor cost controls and product concentration risk given Tyvaso's dominance.

Analysis

United Therapeutics (UTHR) reported mixed second-quarter 2025 results, characterized by strong top-line growth that nonetheless fell short of Wall Street estimates. GAAP revenue increased 11.7% year-over-year to a record $798.6 million, missing consensus by $3.3 million, while GAAP EPS grew 9.6% to $6.41, missing expectations by $0.88. The revenue growth was overwhelmingly driven by the Tyvaso franchise, which generated $469.6 million and now constitutes 58.8% of total sales, underscoring a significant product concentration risk. This growth, alongside strong performance from Orenitram (+16%) and Unituxin (+13%), was partially offset by a 9% decline in the legacy product Remodulin due to generic competition. Profitability was constrained by a 20% surge in SG&A expenses, which included a $21.7 million impairment charge, and a higher tax rate. While management expressed confidence in sustaining double-digit revenue growth, no formal guidance was provided. Key future catalysts include the pivotal TETON 2 trial results expected in September 2025, which could expand Tyvaso's market. The company's financial position remains robust, with nearly $5.0 billion in cash and a newly authorized $1 billion share repurchase program, providing significant flexibility for investment and capital returns.

Key Decisions for Investors

• Investors should focus on the upcoming TETON 2 clinical trial results in September 2025, as a positive outcome is critical to validating the growth trajectory and justifying the increasing reliance on the Tyvaso franchise.
• Given the significant EPS miss driven by a 20% rise in SG&A, it is prudent to monitor subsequent quarters for evidence of improved cost controls and operating leverage to ensure profitability keeps pace with revenue growth.
• The heavy concentration on Tyvaso (58.8% of revenue) represents a material risk; therefore, progress in pipeline assets like ralinepag and the long-term organ manufacturing initiatives should be closely watched for signs of future diversification.
• Consider the company's strong balance sheet and new $1 billion buyback program as a source of potential downside support, but watch for how management balances share repurchases with strategic investments in its pipeline and pre-commercial platforms.